Targeting tumor necrosis factor-α in inflammatory bowel disease: Why, how, and when?

Current Opinion in Gastroenterology

Volumn 19, Issue 4, 2003, Pages 350-357

  Hommes, Daniël W ^a   Van Deventer, Sander J H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTISENSE OLIGONUCLEOTIDE; AZATHIOPRINE; CORTICOSTEROID; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; ONERCEPT; PEPTIDE; SEMAPIMOD; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; ENTERITIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLAMMATION; INTESTINE MUCOSA; LAMINA PROPRIA; MAINTENANCE THERAPY; MUCOSAL IMMUNITY; NONHUMAN; PATHOPHYSIOLOGY; PROPHYLAXIS; RELAPSE; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TERATOGENICITY; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0038676310     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200307000-00005     Document Type: Review

References (54)

1. Neurath MF, Fuss I, Pasparakis M, et al.: Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 1997, 27:1743-1750.
2. Braegger CP, Nicholls S, Murch SH, et al.: Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992, 339:89-91.
3. Cappello M, Keshav S, Prince C, et al.: Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridisation. Gut 1992, 33:1214-1219.
4. Murch SH, Braegger CP, Walker-Smith JA, et al.: Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993, 34:1705-1709.
5. Reinecker HC, Steffen M, Witthoeft T, et al.: Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993, 94:174-181.
6. Nielsen OH, Brynskov J, Bendtzen K: Circulating and mucosal concentrations of tumour necrosis factor and inhibitor(s) in chronic inflammatory bowel disease. Dan Med Bull 1993, 40:247-249.
7. van Deventer SJ: Tumour necrosis factor and Crohn's disease. Gut 1997, 40:443-448 [see comments].
8. D'Haens GR, Geboes K, Peeters M, et al.: Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998, 114:262-267.
9. Bu P, Keshavarzian A, Stone DD, et al.: Apoptosis: one of the mechanisms that maintains unresponsiveness of the intestinal mucosal immune system. J Immunol 2001, 166:6399-6403.
10. Boirivant M, Marini M, Di Felice G, et al.: Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999, 116:557-565. See [11].
11. Ina K, Itoh J, Fukushima K, et al.: Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999, 163:1081-1090. Together with [10], this study demonstrated for the first time the importance of apoptosis in the pathophysiology of Crohn disease.
12. ten Hove T, van Montfrans C, Peppelenbosch MP, et al.: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002, 50:206-211. The authors translated the in vitro and ex vivo experiments with infliximab to the in vivo situation in patients with Crohn disease and showed that apoptosis induction is a relevant process for infliximab success
13. Lugering A, Schmidt M, Lugering N, et al.: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001, 121:1145-1157. This study demonstrated the effect of infliximab on monocyte apoptosis as a potential antiinflammatory mechanism.
14. Sandborn WJ, Hanauer SB, Katz S, et al.: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088-1094.
15. van den Brande JM, Braat H, van den Brink GR, et al.: Hommes DW, Peppelenbosch MP, van Deventer SJ: A possible mechanism for the difference in efficacy between infliximab and etanercept in the treatment of Crohn's disease. Gastroenterology 2003, 124(6):1774-1785. This article is important because it underscores the role of apoptosis in the healing process in Crohn disease and could explain the differences between the effectiveness of etanercept and that of infliximab. This seems relevant for designing future therapeutic anti-TNF-α strategies.
16. Beutler B, Van Huffel C: An evolutionary and functional approach to the TNF receptor/ligand family. Ann N Y Acad Sci 1994, 30:118-133.
17. Farrah T, Smith CA: Emerging cytokine family. Nature 1992, 358:26.
18. Manogue KR vDSCA: Tumour necrosis factor alpha or cachectin. In: Cytokine Handbook. Edited by Thomson AW. London: Academic Press; 1991, 241-256.
19. Carroll MC, Katzman P, Alicot EM, et al.: Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes. Proc Natl Acad Sci U S A 1987, 84:8535-8539.
20. Perez C, Albert I, DeFay K, et al.: A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 1990, 63:251-258.
21. Tartaglia LA, Goeddel DV: Two TNF receptors. Immunol Today 1992, 13:151-153.
22. Kohno T, Brewer MT, Baker SL, et al.: A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci U S A 1990, 87:8331-8335.
23. Lantz M, Gullberg U, Nilsson E, et al.: Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor. J Clin Invest 1990, 86:1396-1402.
24. Vandevoorde V, Haegeman G, Fiers W: Induced expression of trimerized intracellular domains of the human tumor necrosis factor (TNF) p55 receptor elicits TNF effects. J Cell Biol 1997, 137:1627-1638.
25. van Dullemen HM, van Deventer SJ, Hommes DW, et al.: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109:129-135.
26. Targan SR, Hanauer SB, van Deventer SJ, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
27. Rutgeerts P, D'Haens G, Targan S, et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117:761-769.
28. Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549. This study reports on the effectiveness of infliximab maintenance therapy in Crohn disease.
29. Present DH, Rutgeerts P, Targan S, et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
30. Jarvis B, Faulds D: Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999, 57:945-966.
31. Bathon JM, Martin RW, Fleischmann RM, et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
32. D'Haens G, Swijsen C, Noman M, et al.: Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. Am J Gastroenterol 2001, 96:2564-2568.
33. Stephens S, Emtage S, Vetterlein O, et al.: Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 1995, 85:668-674.
34. Stack WA, Mann SD, Roy AJ, et al.: Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997, 349:521-524.
35. Sandborn WJ, Feagan BG, Hanauer SB, et al.: An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001, 120:1330-1338.
36. Feagan BG, Sandborn WJ: A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Gastroenterology 2000, 118:A655.
37. Rutgeerts P, Lemmens L, Van Assche G, et al.: Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003, 17:185-192.
38. Rau R: Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 2002, 61 (Suppl 2):ii70-ii73.
39. Ehrenpreis ED, Kane SV, Cohen LB, et al.: Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999, 117:1271-1277.
40. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al.: An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999, 117:1278-1287.
41. Hommes DW, Peppelenbosch MP, van Deventer SJ: Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 2003, 52:144-151.
42. Cohen PS, Nakshatri H, Dennis J, et al.: CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Proc Natl Acad Sci U S A 1996, 93:3967-3971.
43. Cohen PS, Schmidtmayerova H, Dennis J, et al.: The critical role of p38 MAP kinase in T ceil HIV-1 replication. Mol Med 1997, 3:339-346.
44. Bianchi M, Ulrich P, Bloom O, et al.: An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality. Mol Med 1995, 1:254-266.
45. Bianchi M, Bloom O, Raabe T, et al.: Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J Exp Med 1996, 183:927-936.
46. Hommes D: van den BB, Plasse T, Bartelsman J, Xu C, Macpherson B, Tytgat G, Peppelenbosch M, Van Deventer S: Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002, 122:7-14. This is the first published study to evaluate an inhibitor of the signal transduction pathway MAP kinase for an inflammatory condition.
47. Cohen RD, Tsang JF, Hanauer SB: Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000, 95:3469-3477.
48. Farrell RJ, Shah SA, Lodhavia PJ, et al.: Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000, 95:3490-3497.
49. Hommes DW, van de Heisteeg BH: van der SM, Bartelsman JF, van Deventer SJ: Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital. Inflamm Bowel Dis 2002, 8:81-86.
50. Sandborn WJ, Hanauer SB: Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002, 97:2962-2972. The authors provide an excellent overview and algorithm for clinicians who treat patients with infliximab.
51. Hommes DW, van Deventer SJ: Infliximab therapy in Crohn's disease: Safety issues. Neth J Med 2003, 61:14-19.
52. Baert F, Noman M, Vermeire S, et al.: D' Haens G, Carbonez A, Rutgeerts P: influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608. This article is important for clinicians who treat Crohn disease because outlines several determinants of infliximab success.
53. Hommes DW, van Deventer SJ: Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2003, 124(6): 2002-2003.
54. Boers M, Verhoeven AC, Markusse HM, et al.: van der LS: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997, 350:309-318.